Dr. Reddy’s weight-loss drug Semaglutide rollout in Canada delayed over compliance notice
Dr. Reddy’s share prices plunge more than 5% in early trade on the BSE on Thursday (October 30, 2025) after the regulatory setback, which comes at a time when the company is betting big on new launches to offset decline in U.S. revenue from cancer drug Revlimid’s generic Lenalidomide. Generic drugmaker Dr. Reddy’s Laboratories plans…